The Food and Drug Administration yesterday released a final rule allowing states, territories and Indian tribes to establish programs to import certain FDA-approved prescription drug and biological products from Canada.

Pharmacists and wholesalers could co-sponsor the programs, which would have to demonstrate that the imported products pose no additional risk to public health and safety and would cost consumers significantly less, and may be able to establish them in the future, FDA said.

The agency also issued final guidance describing procedures for drug makers importing foreign-made prescription drug and biological products approved by the FDA. In addition, the Centers for Medicare & Medicaid Services issued guidance on the rule’s implications for the Medicaid Drug Rebate Program.

President Trump in July issued an executive order directing the agency to take actions to allow for the importation and re-importation by states, wholesalers and pharmacies of Food and Drug Administration-approved drugs from Canada.

Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…
Headline
The Administration for Strategic Preparedness and Response Feb. 18 announced an investment that will focus on resolving a frequent shortage of oseltamivir,…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the…
Headline
The White House yesterday launched TrumpRx, the direct-to-consumer platform that will serve as a hub to direct cash-paying consumers to drug manufacturers…
Headline
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to disclose…
Headline
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell…